<DOC>
	<DOC>NCT00602303</DOC>
	<brief_summary>The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to DemadexÂ® Tablets, 20 mg (Roche) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.</brief_summary>
	<brief_title>Bioequivalency Study of Torsemide Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Torsemide</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Torsemide or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>